Tacrolimus

Manufactured by Novartis

Sourced in Japan, Switzerland

Tacrolimus is a pharmaceutical product that functions as a calcineurin inhibitor. It is used in the production and manufacture of laboratory equipment and supplies.

Automatically generated - may contain errors

Lab products found in correlation

Cyclosporine a, by Novartis (1 mentions) Prograft, by Astellas Pharma (1 mentions) Certican, by Novartis (1 mentions) Simulect, by Novartis (1 mentions) Cellcept, by Roche (1 mentions) Everolimus, by Novartis (1 mentions)

2 protocols using tacrolimus

Calcineurin Inhibitor Effects on Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cyclosporine A and tacrolimus were purchased from Novartis Pharma Japan and Astellas Pharma Japan, respectively. For the proliferation assay, cells were cultured in medium supplemented with 0.1 μm Cyclosporine A or 0.5 μm tacrolimus until the end of the IncuCyte proliferation assay. To confirm the suppression of calcineurin activity under the treatment with Cyclosporine A and tacrolimus, cell lysates were extracted 96 h after treatment with CNIs and calcineurin activity was compared between extracted cell lines with or without the treatment of CNIs.

Niitsu H., Hinoi T., Kawaguchi Y., Sentani K., Yuge R., Kitadai Y., Sotomaru Y., Adachi T., Saito Y., Miguchi M., Kochi M., Sada H., Shimomura M., Oue N., Yasui W, & Ohdan H. (2016). KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer. Oncogenesis, 5(8), e253-.

+ Open protocol

+ Expand

Immunosuppressive Regimen for Lung Transplant

Check if the same lab product or an alternative is used in the 5 most similar protocols

Induction therapy consists of basiliximab (Simulect; Novartis Pharma, Basel, Switzerland). Maintenance immunosuppression consists of a calcineurin inhibitor (CNI)-based immunosuppressive regimen (trough levels 7-10) combined with prednisolone (0.05-0.15 mg/kg) and mycophenolate mofetil (CellCept; Roche, Basel, Switzerland). tacrolimus (Prograft; Astellas Pharma, Staines, UK) is the most commonly used CNI in our center. Upon significant decline of renal function patients receive a quadruple immunosuppressive scheme adding everolimus (Certican; Novartis Pharma, Basel, Switzerland) to enable CNI dose reduction (tacrolimus trough levels 3-4; everolimus trough levels 3-4). All patients receive Pneumocystis Jerovici prophylaxis (co-trimoxazole or inhaled pentamidine) and cytomegalovirus prophylaxis (valganciclovir) if applicable. Inhaled amphotericin B is used as fungal prophylaxis in the first months and azithromycin is used as standard CLAD prophylaxis in all patients unless patients experience side-effects.

Wijbenga N., Hoek R.A.S., Mathot B.J., Seghers L., Moor C.C., Aerts J.G.J.V., Bos D., Manintveld O.C, & Hellemons M.E. (2023). Diagnostic performance of electronic nose technology in chronic lung allograft dysfunction. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 42(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!